Le Lézard
Classified in: Health

Muscle Fat Replacement and Functional Decline in Neuromuscular Disorders - Quantitative Skeletal Muscle MRI in Clinical Trials, Upcoming Webinar Hosted by Xtalks


TORONTO, Sept. 25, 2020 /PRNewswire-PRWeb/ -- Drug development in neuromuscular disorders needs robust biomarker and clinical endpoints to study drug efficacy in early and late stage trials. Ultimately, functional decline and motor disability are the main clinical manifestations of neuromuscular disorders (NMD) and used for approval of novel therapeutics. However, assessment of changes in neurological function is associated with large variability and many NMDs are slowly progressive, thus limiting its feasibility as efficacy endpoint in early clinical development.

One of the most promising efficacy biomarkers in neuromuscular disorders for early clinical development is skeletal muscle MRI. The recent development of quantitative skeletal MRI biomarkers, describing the extent of muscle atrophy and muscle fat infiltration and replacement, has enabled the detection and measurement of NMD earlier and more precisely compared to clinical endpoints. Standardized quantitative skeletal muscle MRI has been used to objectively evaluate NMD across different disease stages and measure longitudinal changes in diseases with complex onset patterns and slow progression such as FSHD (facioscapulomuscular dystrophy) and DMD (Duchenne Muscular Dystrophy).

Join Sarah Sherlock, PhD, Director Clinical and Translational Imaging, Pfizer, Diego Cadavid, MD, Senior Vice President, Clinical Development, Fulcrum Therapeutics and Per Widholm, MD, Lead Scientist, MSK, AMRA Medical Research in a live webinar on Wednesday, October 7, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Muscle Fat Replacement and Functional Decline in Neuromuscular Disorders ? Quantitative Skeletal Muscle MRI in Clinical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

 

SOURCE Xtalks


These press releases may also interest you

at 11:00
The most recent data on the evolution of COVID-19 in Québec show 1,038 new cases, bringing the total number of people infected to 94,429. Also, 2 deaths have occurred in the last 24 hours, to which are added 1 death that occurred between October...

at 11:00
NOTICE OF AUTHORIZATION (CERTIFICATION) AND HEARING TO APPROVE PROPOSED SETTLEMENT WITH BAUSCH HEALTH COMPANIES INC. (FORMERLY VALEANT PHARMACEUTICALS INC.) Read this notice carefully. A settlement may affect your legal rights. THIS NOTICE IS TO...

at 11:00
The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, is hosting a low vision webinar to inform eye care professionals about the many opportunities to greatly...

at 11:00
Is it possible to fight infectious disease like COVID-19 ? and create a more just world in the process? The founders of Partners In Health, a nonprofit social justice organization with deep experience in treating infectious disease...

at 11:00
Connecticut personal injury and medical malpractice attorney, Russell Berkowitz from Berkowitz Hanna, was recently named in the top six percent of practicing attorneys in the country by the attorney-rating organization, Best Lawyers. Berkowitz, a...

at 11:00
While most cancers happen by chance due to a variety of factors, about 10% of the time, cancer is linked to a single change in a gene, or mutation, that has been passed down from family members. This is referred to as hereditary cancer. A person who...



News published on 25 september 2020 at 08:30 and distributed by: